Summary
Mother-to-child transmission of HIV and Syphilis causes approximately 305,000 fetal and neonatal deaths every year and leaves 215,000 infants at increased risk of dying from prematurity, low-birth-weight or congenital disease. An accurate diagnosis of diagnostic-antibodies and a simple treatment during the first weeks of pregnancy could stop all those deaths.
Here, I propose the development of a new technique to be used to measure antibodies directly in whole blood. These will combine the multiplexed (i.e., multiple tests in parallel on one sample), quantitative performance of laboratory-based tests with the portability and low-cost of point-of-care tests. As the first step, I will design, optimize and test nanometer-scale, DNA-based “switches” that undergo a dramatic change in conformation (closed/open) upon recognizing its target antibody. I will use this conformational change to generate a large, easily measurable electronic (electrochemical) signal, which I will then employ in and validate as laboratory-scale, single-test devices using both purified antibodies and authentic human samples. I will then integrate the set of sensors exhibiting good clinical performances into a single, paper-based microfluidic sample handing device (similar to the home pregnancy test) to generate a low-cost platform capable of measuring multiple diagnostic antibodies in a single finger-prick blood sample.
The final and main goal in the DNA-SPADE project is the development of a working prototype diagnostic device, which I will design accordingly to suggestions/inputs from a variety of possible final users (such as nurses and doctors).
Here, I propose the development of a new technique to be used to measure antibodies directly in whole blood. These will combine the multiplexed (i.e., multiple tests in parallel on one sample), quantitative performance of laboratory-based tests with the portability and low-cost of point-of-care tests. As the first step, I will design, optimize and test nanometer-scale, DNA-based “switches” that undergo a dramatic change in conformation (closed/open) upon recognizing its target antibody. I will use this conformational change to generate a large, easily measurable electronic (electrochemical) signal, which I will then employ in and validate as laboratory-scale, single-test devices using both purified antibodies and authentic human samples. I will then integrate the set of sensors exhibiting good clinical performances into a single, paper-based microfluidic sample handing device (similar to the home pregnancy test) to generate a low-cost platform capable of measuring multiple diagnostic antibodies in a single finger-prick blood sample.
The final and main goal in the DNA-SPADE project is the development of a working prototype diagnostic device, which I will design accordingly to suggestions/inputs from a variety of possible final users (such as nurses and doctors).
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/795635 |
| Start date: | 07-01-2019 |
| End date: | 06-01-2021 |
| Total budget - Public funding: | 170 121,60 Euro - 170 121,00 Euro |
Cordis data
Original description
Mother-to-child transmission of HIV and Syphilis causes approximately 305,000 fetal and neonatal deaths every year and leaves 215,000 infants at increased risk of dying from prematurity, low-birth-weight or congenital disease. An accurate diagnosis of diagnostic-antibodies and a simple treatment during the first weeks of pregnancy could stop all those deaths.Here, I propose the development of a new technique to be used to measure antibodies directly in whole blood. These will combine the multiplexed (i.e., multiple tests in parallel on one sample), quantitative performance of laboratory-based tests with the portability and low-cost of point-of-care tests. As the first step, I will design, optimize and test nanometer-scale, DNA-based “switches” that undergo a dramatic change in conformation (closed/open) upon recognizing its target antibody. I will use this conformational change to generate a large, easily measurable electronic (electrochemical) signal, which I will then employ in and validate as laboratory-scale, single-test devices using both purified antibodies and authentic human samples. I will then integrate the set of sensors exhibiting good clinical performances into a single, paper-based microfluidic sample handing device (similar to the home pregnancy test) to generate a low-cost platform capable of measuring multiple diagnostic antibodies in a single finger-prick blood sample.
The final and main goal in the DNA-SPADE project is the development of a working prototype diagnostic device, which I will design accordingly to suggestions/inputs from a variety of possible final users (such as nurses and doctors).
Status
CLOSEDCall topic
MSCA-IF-2017Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
